Mineralys Therapeutics, Inc. MLYS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.15M-14.6% | $1.03M+55.1% | $1.21M+142% | $1.01M+940% | $1.35M-74.9% | ||
| $652.47M+84.1% | $661.39M+222% | $599.8M+124% | $335.27M+5.4% | $354.51M+2.2% | ||
| $32K-15.8% | $38K-28.3% | $7K-89.9% | $22K— | $38K— | ||
| —— | —— | —— | —— | —— | ||
| $652.86M+83.9% | $661.81M+221% | $599.95M+124% | $335.72M+5.4% | $354.94M+2.2% | ||
| $1.12M+199% | $2.02M+321% | $1.12M-63.9% | $3.16M+85.4% | $373K-91.2% | ||
| $14.72M+10.0% | $15.11M+3.2% | $23.52M-24.9% | $22.17M-21.9% | $13.39M-30.3% | ||
| 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | ||
| -$496.51M-44.0% | -$457.17M-51.1% | -$424.94M-67.6% | -$388M-96.7% | -$344.73M-121% | ||
| $638.14M+86.8% | $646.69M+238% | $576.43M+143% | $313.55M+8.1% | $341.56M+4.1% | ||
| $652.86M+83.9% | $661.81M+221% | $599.95M+124% | $335.72M+5.4% | $354.94M+2.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Mineralys Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 44.33 — current assets exceed current liabilities.
- Where does Mineralys Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.